SNOA

Sonoma Pharmaceuticals, Inc. (SNOA) ESG Analysis Analysis (2026)

Invetso Score: 5.9/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

SNOA’s R&D intensity suggests some product and process innovation, but the absence of peer environmental disclosures limits evidence of superior emissions or resource management.

Low leverage can support capital flexibility for environmental compliance and transition spending, yet it does not itself demonstrate stronger environmental performance than peers.

No disclosed environmental metrics on energy use, emissions, waste, or water constrain assessment, leaving SNOA closer to a neutral peer position than a leader.

Compared with peers that report quantified climate targets and operational footprints, SNOA appears less transparent, which weakens relative environmental positioning despite limited visible risk.

Social

Score:

SNOA’s low stock-based compensation to revenue indicates restrained dilution, but it provides little direct evidence of stronger employee alignment or labor practices versus peers.

R&D spending can support safer or more useful products over time, yet the available data do not show superior customer, workforce, or community outcomes relative to peers.

The lack of disclosed workforce metrics, safety data, and diversity information limits confidence in social performance, keeping SNOA below more transparent peers.

Relative to peers with published human-capital and product-responsibility indicators, SNOA’s social profile is harder to verify, which caps its positioning at a moderate level.

Governance

Score:

SNOA’s low debt-to-equity ratio indicates conservative balance-sheet governance, which reduces creditor pressure and supports oversight flexibility versus more levered peers.

Modest stock-based compensation suggests comparatively restrained equity dilution, but it does not by itself establish stronger board independence or shareholder protections.

The available metrics do not reveal audit quality, board structure, or controversy history, so governance assessment remains incomplete relative to better-disclosed peers.

Compared with peers that provide fuller governance disclosure, SNOA shows some discipline in capital structure but lacks enough evidence to rank as a strong leader.

Overall Score

Score:

SNOA’s ESG positioning is moderate because limited disclosure and only modestly supportive capital-discipline signals leave it broadly in line with, but not ahead of, peers.

Score Driver: Insufficient ESG Disclosure Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Sonoma Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →